Merve Isler, Founder and CEO of Marvelous, sits down with Ventureport to discuss how AI can help revenue teams find the right rooms, guests and opportunities.
Updated
July 3, 2026 11:39 AM
.jpg)
Marvelous, an AI product company. PHOTO: MARVELOUS
Most B2B sales teams spend their days inside software. They track leads in a customer relationship management (CRM) tool, send emails, build outbound lists and measure every digital touchpoint. Still, many important business relationships move forward in person. A dinner after a conference, a small founder roundtable or a private customer event can do what dozens of cold emails cannot: build trust quickly.
That is the gap Marvelous wants to fill. The bootstrapped San Francisco-based AI startup is building what founder and CEO Merve Isler calls “Salesforce, but for real life”. Her idea is simple: if companies already use software to manage digital sales, they should also have software to manage the real-world moments that help close deals.
Marvelous brings data, automation and targeting into in-person go-to-market (GTM) work. It helps B2B sales, revenue, marketing and growth teams plan in-person events such as curated dinners, launch events, mixers, happy hours and conference side events. These formats are already familiar to companies selling to enterprise buyers. The problem is that they are often managed through spreadsheets, venue calls, scattered guest lists and manual follow-ups.
That creates two problems. First, the process is slow. Teams can spend weeks figuring out who to invite, where to host and how to manage responses. Second, the return is hard to measure. Companies spend heavily on conferences, dinners and private events, yet they often do not have a clear way to know whether an event will influence pipeline before they commit the budget.
Marvelous wants to pull those pieces into one AI-powered event management platform.
“Our main target customer is revenue and sales teams,” Isler said. “Because about 40% of deals close in person, but there's no infrastructure built for that—so that's what we do.”
For Isler, the idea comes from experience. Before starting Marvelous, she worked at Google from Istanbul, managing developer product launches and go-to-market programs across Turkey, Central Asia and the Caucasus. During that time, she helped build more than 100 communities around the world and coordinated thousands of events a year across eleven time zones. The work was fast, local and very manual.
That experience shaped the foundation for Marvelous. Isler saw that building products had become easier, while distribution remained difficult. A startup can now ship software faster than ever. Reaching the right people, in the right setting, is still a different challenge.
At Google, Isler had to understand how people gathered, communicated and built trust in different markets. A product launch might require developer meetups in dozens of cities, but the right approach could change from country to country. In Kazakhstan, she said, Telegram worked better than WhatsApp. In Afghanistan, Facebook mattered more. Each market had its own habits, and growth depended on understanding those details. Those details and adapt quickly.
Marvelous grew out of that playbook. Isler saw that offline distribution had patterns, even when it looked chaotic from the outside. The right guest list, the right room, the right timing and the right follow-up could change the outcome of a sales conversation. Most of that knowledge, however, lived in people’s heads. Marvelous is her attempt to turn it into software.
Inside the platform, a company can start by choosing the kind of satellite event it wants to host: a launch event, a mixer, a happy hour, a brunch, a lunch or a dinner. From there, users can connect their CRM. When Salesforce is connected, Marvelous analyzes contacts and creates relationship scores based on signals such as buying intent, past event activity and how warm a relationship appears to be. If a team also uses an event platform such as Luma or Eventbrite, Marvelous can bring that event data into the picture as well.

The product is built around Maven, Marvelous’ AI assistant. Maven can help plan an event through Slack, iMessage or the Marvelous platform itself. For instance, a user might ask Maven to plan an executive dinner for 18 people within a set budget. From there, Maven can find warm contacts, estimate who is likely to attend, build a guest list, recommend venues, send invitations and run follow-up sequences across email, LinkedIn and SMS. The goal is to let sales teams focus on conversations and closing deals instead of worrying about logistics. Put simply, Marvelous helps a company find the right guests, secure the right venue and understand which event format is likely to work. Instead of guessing whether a US$10,000 dinner will pay off, the company gets a clearer view of the potential return.

AI Insiders, Marvelous’ invite-only network of verified AI and enterprise leaders, is also part of the company’s go-to-market strategy. Rather than asking every customer to build an event from scratch, Marvelous can group several companies that want to reach the same audience into one curated event. Such a setting creates revenue, product feedback and fresh data about what works in different markets. The network spans verticals such as cybersecurity, fintech, robotics, healthcare AI and enterprise SaaS. It now includes members from more than 475 companies, with C-level executives making up nearly half of the community. So far, AI Insiders has facilitated more than 2,000 introductions and contributed to over US$560 million in deals. Isler describes it as one of Marvelous’ strongest go-to-market channels.
The first AI Insiders event took place at AWS GenAI Loft in San Francisco in April 2026. It brought together 150 curated guests, including AI founders, tier-one investors, enterprise executives and researchers for an evening focused on high-impact conversations and collaboration.
The timing may work in Marvelous’ favor: Digital outreach is getting louder, and AI will make it easier for companies to send more emails, messages and automated pitches. That may make high-trust in-person conversations more valuable, especially in enterprise sales where relationships take time. At the same time, event budgets need proof. Revenue leaders want to know whether a dinner, roadshow or customer event is worth the cost.
Marvelous is betting that offline sales will become a measurable category for software. If the company can prove that its relationship scores, event intelligence and AI agent help teams create a stronger pipeline, it could become an important tool for B2B go-to-market teams. The core message of Marvelous is easy to understand: the deals may happen in the room, but data can still power the room.
Keep Reading
A closer look at how machine intelligence is helping doctors see cancer in an entirely new light.
Updated
January 8, 2026 6:33 PM

Serratia marcescens colonies on BTB agar medium. PHOTO: UNSPLASH
Artificial intelligence is beginning to change how scientists understand cancer at the cellular level. In a new collaboration, Bio-Techne Corporation, a global life sciences tools provider, and Nucleai, an AI company specializing in spatial biology for precision medicine, have unveiled data from the SECOMBIT clinical trial that could reshape how doctors predict cancer treatment outcomes. The results, presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlight how AI-powered analysis of tumor environments can reveal which patients are more likely to benefit from specific therapies.
Led in collaboration with Professor Paolo Ascierto of the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, the study explores how spatial biology — the science of mapping where and how cells interact within tissue — can uncover subtle immune behaviors linked to survival in melanoma patients.
Using Bio-Techne’s COMET platform and a 28-plex multiplex immunofluorescence panel, researchers analyzed 42 pre-treatment biopsies from patients with metastatic melanoma, an advanced stage of skin cancer. Nucleai’s multimodal AI platform integrated these imaging results with pathology and clinical data to trace patterns of immune cell interactions inside tumors.
The findings revealed that therapy sequencing significantly influences immune activity and patient outcomes. Patients who received targeted therapy followed by immunotherapy showed stronger immune activation, marked by higher levels of PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells. Those who began with immunotherapy benefited most when PD-1+ CD8 T-cells engaged closely with PD-L1+ CD4 T-cells along the tumor’s invasive edge. Meanwhile, in patients alternating between targeted and immune treatments, beneficial antigen-presenting cell (APC) and T-cell interactions appeared near tumor margins, whereas macrophage activity in the outer tumor environment pointed to poorer prognosis.
“This study exemplifies how our innovative spatial imaging and analysis workflow can be applied broadly to clinical research to ultimately transform clinical decision-making in immuno-oncology”, said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne.
The collaboration between the two companies underscores how AI and high-plex imaging together can help decode complex biological systems. As Avi Veidman, CEO of Nucleai, explained, “Our multimodal spatial operating system enables integration of high-plex imaging, data and clinical information to identify predictive biomarkers in clinical settings. This collaboration shows how precision medicine products can become more accurate, explainable and differentiated when powered by high-plex spatial proteomics – not limited by low-plex or H&E data alone”.
Dr. Ascierto described the SECOMBIT trial as “a milestone in demonstrating the possible predictive power of spatial biomarkers in patients enrolled in a clinical study”.
The study’s broader message is clear: understanding where immune cells are and how they interact inside a tumor could become just as important as knowing what they are. As AI continues to map these microscopic landscapes, oncology may move closer to genuinely personalized treatment — one patient, and one immune network, at a time.